NASDAQ:ABAX

Abaxis (ABAX) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$83.00
$83.00
50-Day Range
N/A
52-Week Range
$43.66
$83.98
Volume
N/A
Average Volume
167,754 shs
Market Capitalization
N/A
P/E Ratio
42.35
Dividend Yield
N/A
Price Target
N/A
ABAX stock logo

About Abaxis Stock (NASDAQ:ABAX)

Abaxis, Inc. develops, manufactures, markets, and sells portable blood analysis systems for use in human or veterinary patient care to provide rapid blood constituent measurements for clinicians worldwide. It operates in two segments, Medical Market and Veterinary Market. The company offers Piccolo chemistry analyzers with rapid blood constituent measurements for use in human patient care; and Piccolo profiles that are single-use medical reagents. It also provides VetScan VS2, a chemistry, electrolyte, immunoassay, and blood gas analyzer delivering results from a sample of whole blood, serum, or plasma; VetScan profiles, which are packaged as single-use plastic veterinary reagent discs; and VetScan HM5, VetScan HM2, VetScan HMII, and VetScan HMT hematology instruments, as well as reagent kits for veterinary applications. In addition, the company offers VetScan VSpro that assists the diagnosis and evaluation of suspected bleeding disorders, toxicity/poisoning, disseminated intravascular coagulation evaluation, hepatic disease, monitoring therapy, and disease progression states; VetScan VSpro coagulation test to evaluate prothrombin and the activated partial thromboplastin times; VetScan VSpro fibrinogen test for in-vitro determination of fibrinogen levels in equine platelet poor plasma from a citrated stabilized whole blood sample; i-STAT that delivers blood gas, electrolyte, chemistry, and hematology results; VetScan UA, a urinalysis solution; and VetScan SA, which is designed to perform urine microscopy. Further, it provides VetScan rapid tests for the detection of various diseases, as well as sells products developed through its patented Orbos discrete lyophilization process to companies for other applications. The company sells its products through direct sales force and independent distributors. Abaxis, Inc. was founded in 1989 and is headquartered in Union City, California.

ABAX Stock News Headlines

AI finds its first serious application
AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.
If you have $2,500 bucks… check this out
This computer whiz has been averaging 234% per year with an undefeated strategy he calls… The “Income Glitch” And he’s been making out like a bandit with a 100% success rate on over 64 trade opportunities!
Veterinary Diagnostic Market by 2030
See More Headlines
Receive ABAX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Abaxis and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
4/26/2018
Today
4/29/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Measuring & Controlling Devices
Sub-Industry
Health Care Equipment
Current Symbol
NASDAQ:ABAX
CUSIP
00256710
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Optionable
Beta
N/A
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. Clinton H. Severson (Age 70)
    Chairman & CEO
  • Mr. Donald P. Wood (Age 66)
    Pres & COO
  • Mr. Ross Taylor Jr. (Age 55)
    CFO, VP of Fin. & Sec.
  • Dr. Kenneth P. Aron Ph.D. (Age 65)
    Chief Technology Officer
  • Dr. Craig M. Tockman DVM (Age 58)
    VP of Animal Health Sales and Marketing - North America

ABAX Stock Analysis - Frequently Asked Questions

How were Abaxis' earnings last quarter?

Abaxis, Inc. (NASDAQ:ABAX) issued its earnings results on Thursday, April, 26th. The medical research company reported $0.42 EPS for the quarter, topping the consensus estimate of $0.32 by $0.10. The medical research company had revenue of $67.90 million for the quarter, compared to analyst estimates of $66.02 million. The firm's revenue was up 16.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.33 EPS.

Is Abaxis a good dividend stock?

Abaxis (NASDAQ:ABAX) pays an annual dividend of $0.72 per share and currently has a dividend yield of 0.00%. The dividend payout ratio is 36.73%. This payout ratio is at a healthy, sustainable level, below 75%.
Read our dividend analysis for ABAX.

What other stocks do shareholders of Abaxis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Abaxis investors own include Skyworks Solutions (SWKS), Wells Fargo & Company (WFC), Abbott Laboratories (ABT), Allergan (AGN), Akorn (AKRX), Gilead Sciences (GILD), NXP Semiconductors (NXPI), Amicus Therapeutics (FOLD), JetBlue Airways (JBLU) and Mylan (MYL).

This page (NASDAQ:ABAX) was last updated on 4/29/2024 by MarketBeat.com Staff

From Our Partners